Haymarket Media, Inc.
Subscribe Issue Archive Contact Us About Us Advertise Affiliates PRWeek UK PRReport Germany PRWeek Asia
 
PRWeek US
  • Home
  • News
    •  Analysis
    •  In Brief
    •  Sectors
    •  Podcasts
    •  Newsletters
  • Features
    •  Cover Stories
    •  Opinion
    •  Web Exclusives
    •  Roundtables
  • Reports
    •  Agency Excellence Survey
    •  Agency Business Report
    •  Salary Survey
    •  Marketing Management Survey
    •  CEO Survey
    •  Diversity Survey
    •  Cause Survey
    •  Power List
    •  Career Guide
  • Blogs
    •  The Cycle
    •  The Editor's Blog
    •  Page Views
  • Events
    •  PRWeek Awards
    •  Webcasts
    •  Conferences
  • Jobs
  • Directory
  • Subscribe
    •  Customer Service
    •  Newsletters
  • About Us
  • Podcasts
  • Hot Topics:
  • Healthcare
  • Consumer
  • Technology
  • Media
  • Public Affairs
  • Corporate
  • Green
  • 2008 Campaign
Login | Register  
Home > Blogs > The Cycle
The Cycle

Posted February 12, 2009

YouTube seems to be the social media trend for Big Pharma so far this year. In the past week, both Sanofi-Aventis and AstraZeneca launched channels targeting specific diseases.

Sanofi’s , an unbranded effort that’s part of the “GoInsulin” campaign, personal stories of patients with diabetes and is the pharmaceutical company’s first YouTube venture. It does not mention Lantus, Sanofi’s insulin therapy; instead it offers general information about insulin.

AstraZeneca’s , considered the Symbicort brand channel, stories of patients affected by asthma. The company also launched a microsite, myasthmastory.com, although a spokesperson told PRWeek it is not part of a larger PR campaign for the asthma drug.

Mark Senak at Eye on FDA:

“Both of these efforts are breathtaking in that they appear deliberate attempts to break the stranglehold that regulatory concerns have had on social media in general and YouTube in particular.  They also both go way beyond what anyone has accomplished so far in terms of creativity and style and in an effort to engage patients.”

The two pharma companies join Johnson & Johnson, Abbott Labs, and GlaxoSmithKline in the YouTube space.

Related Posts
  • YouTube opened a channel exclusively for Congress today - sans ads, which keeps it aligned with prev...
  • Meredith and Comcast partner for Video On Demand
    Meredith and Comcast are joining together to launch a family-focused Video On Demand, scheduled to r...
  • YouTube rolled out a new channel that encourages voters to take out their video cameras come electio...
  • Debate 2.0

Filed under: Branding, Consumer, Healthcare, Public Relations, Social Media, Web sites

Tags:Abbott Labs, AstraZeneca, Eye on FDA, GlaxoSmithKline, Johnson & Johnson, Sanofi-Aventis, Symbicort,

The Cycle

For both journalists and communicators, the news cycle never ends. At The Cycle, PRWeek’s editorial team offers commentary and viewpoints on how the latest marketing, business, political, and cultural news impact the PR industry.

Agency Business Report
Make sure your firm is included in the 2008 Agency Rankings, published in the April 21 issue. To download the rankings form, click here.

Tags
AIG Anheuser-Busch Apple Associated Press Baltimore Sun Barack Obama Burson-Marsteller California CBS Chicago Tribune CNN Congress Da Vinci Dell Edelman Editor & Publisher Hillary Clinton Huffington Post InBev John McCain Keith Olbermann Los Angeles Los Angeles Times Marcus Brauchli Mark Penn Microsoft MSNBC News Corp New York Post New York Times NIRI PRSA PRWeek recession Scott McClellan TechCrunch The New York Times Tribune Co. Wall Street Journal Washington Post Weber Shandwick WPP Yahoo

RECENT POSTS

Agent Provocateur updates its status

Trevor Project gets pro bono digital support

Waste Management forgoes pre-release, announces negative results

Charter Communications to file for Chapter 11 by April 1

Surveys show recall awareness is high, but brand confusion persists



Authors
  • Aarti Shah (83)
  • Alexandra Bruell (74)
  • Beth Krietsch (5)
  • Erica Iacono (12)
  • Frank Washkuch (124)
  • Gideon Fidelzeid (1)
  • Hamilton Nolan (8)
  • Irene Chang (57)
  • Jaimy Lee (25)
  • Keith O'Brien (114)
  • Kimberly Maul (146)
  • Marc Longpre (1)
  • Matthew McGevna (2)
  • Michael Bush (91)
  • Nicole Zerillo (31)
  • Randi Schmelzer (1)
  • Rose Gordon (29)
  • Ted McKenna (90)
  • Tonya Garcia (127)

Archives
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006

Categories
  • 1
  • 2008 Campaign
  • Advertising
  • Agency-client relationship
  • All PRWeek blogs
  • Announcements
  • Arts & Entertainment
  • Automotive
  • Awards
  • Blogs
  • Branding
  • Careers
  • Consumer
  • Corporate Communications
  • Corporate Reputation
  • Crisis Communications
  • CSR
  • Culture
  • Diversity
  • Education
  • Events
  • Financial/IR
  • Food and Beverage
  • Green
  • Guerilla/WOM
  • Healthcare
  • HR
  • Industry/Energy
  • Internal Communications
  • International
  • Journalism 2.0
  • layoffs
  • Lobbying
  • Marketing
  • Measurement/Monitoring
  • Media
  • Miscellaneous
  • Mobile Marketing
  • Multicultural
  • Music
  • New Media
  • Partially there
  • Politics
  • Product Launch
  • PRWeek
  • PRWeek Awards
  • Public Affairs
  • Public Relations
  • Social Media
  • Sports
  • Technology
  • Travel
  • Viral Video
  • Web sites

  • Blogroll

    • WordPress.com
    • WordPress.org

Home | News | Newsletters | Blogs | Directory | PR Jobs | Events | Subscribe | Contact Us | About Us | Editorial Calendar | Reprints | Advertising

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions